Source: CureToday articles
A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.
Recent Content
- Renowned Breast Cancer Physician-Scientist Dr. Hope S. Rugo to Lead City of Hope’s Women’s Cancers Program
- Measles Cases Climb to 800 in United States as Outbreak Spreads Across Borders
- Reassessing Immunotherapy Use in Advanced Renal Cell Carcinoma
- SPPCP 2025: Highlights and Can’t-Miss Sessions From the Virtual Conference on Pain and Palliative Care Pharmacy
- First-Line Focus: Molecular Testing and Guideline-Directed Therapy in EGFR-Positive NSCLC
- Momelotinib Shows Strong Efficacy in JAK-Exposed Myelofibrosis Patients
- Recognizing Symptoms During Head and Neck Cancer Awareness Month
- Overcoming Challenges in NSCLC Management From a Pharmacist’s Perspective
- AI Tool May Better Predict Transplant Risk in Myelofibrosis
- Study: Vision Impairment Signals Linked to Semaglutide Use